Lupin dispatches COVID-19 medication Favipiravir in India at Rs 49 for each tablet Kumar Jeetendra | August 5, 2020 Drug major Lupin on Wednesday announced the launch of its Favipiravir medication under the brand name’Covihalt’ for its treatment patients with mild to moderate COVID-19 symptoms at Rs 49 per pill in India. Favipiravir has received authorisation from the Drug Controller General of India (DCGI) for emergency use, Lupin said in a regulatory filing. Its …
Wockhardt accomplices with UK govt for COVID-19 vaccines Kumar Jeetendra | August 4, 2020 Drug firm Wockhardt on Monday said it has entered into an agreement with the UK authorities to fill-finish COVID-19 vaccines, and will tackle manufacturing in its centre in North Wales. The manufacturing will be undertaken at CP Pharmaceuticals, a subsidiary of the firm based in North Wales, Wockhardt said in a statement. As per the …
U in Discussions to Procure Sanofi Bargain for coronavirus vaccine Kumar Jeetendra | August 1, 2020 Sanofi SA and GlaxoSmithKline Plc on Friday said they are in advanced discussions to supply up to 300 million doses of an experimental COVID-19 vaccine to the 27-country European Union. Equipped with an emergency fund of more than 2 billion euros (Â#1.80 billion), the European Commission would like to strike deals up to six drugmakers …
Pfizer, BioNTech to flexibly 120 million doses of coronavirus immunization to Japan Kumar Jeetendra | July 31, 2020 Pfizer Inc and BioNTech SE have consented to provide Japan with 120 million doses of their mRNA-based vaccine candidate against the novel coronavirus in the first half of 2021, the companies said on Friday. The companies said, assuming achievement of the vaccine in clinical studies, they are on track to look for regulatory review to …
Moderna means to cost coronavirus antibody at $50-$60 per course: Report Kumar Jeetendra | July 29, 2020 Moderna Inc will cost its coronavirus vaccine at $50 To $60 a course, at $11 more than a different drug from Pfizer Inc and also BioNTech, the Financial Times reported about July 28, citing unnamed sources. Moderna’s proposed cost for a two-dose course marketed to Governments contrasts with $39 to get 2 doses below a …
Sanofi, GSK to gracefully up to 60 million dosages of COVID-19 antibody to UK Kumar Jeetendra | July 29, 2020 Sanofi And GSK said they had reached a deal with Britain to provide it with as much as 60 million doses of an expected COVID-19 vaccine, and that discussions with different authorities were ongoing. No Vaccine has been prescribed to treat or protect against COVID-19, the respiratory disorder caused by the new coronavirus which has …
India’s Hetero Labs wins endorsement to dispatch COVID-19 medication favipiravir Kumar Jeetendra | July 29, 2020 India’s Hetero Labs Ltd said on Wednesday it received neighborhood regulatory approval to start its own version of antiviral medication favipiravir for the treatment of COVID-19. The drug, priced in 59 rupees (79 cents) each tablet, will probably be Available at drug stores from Wednesday, independently held Hetero explained.
Emergent BioSolutions signs $174 million arrangement to make AstraZeneca’s potential COVID-19 antibody Kumar Jeetendra | July 27, 2020 AstraZeneca in June chose Emergent to assist make 300 million doses of its possible COVID-19 vaccine vowed to the USA. AstraZeneca has signed manufacturing deals internationally to meet its goal of earning 2 billion gallons of this vaccine, for example with just two Bill Gates-backed ventures and a $1.2 billion deal with the US authorities. …
Minitsry of Health rules against incorporating Itolizumab in clinical administration convention for COVID-19 Kumar Jeetendra | July 26, 2020 The National Task Force on COVID-19 has ruled against incorporating Itolizumab medicate in clinical administration conventions for rewarding the malady despite the fact that the DCGI has affirmed its “confined crisis use” in contaminated patients, official sources said. Considering the neglected clinical needs in COVID-19, Itolizumab, a previously endorsed medication of Biocon, utilized for rewarding …
Cipla receives regulatory approval for launch of Ciplenza in India to treat mild to moderate COVID-19 Kumar Jeetendra | July 24, 2020 Mumbai, India; July 24, 2020: Cipla Limited (BSE: 500087; NSE: CIPLA EQ, hereinafter referred to as “Cipla”), today announced that it has been granted regulatory approval by the Drug Controller General of India (DCGI) for the launch of Favipiravir in the country under the brand name Ciplenza. The accelerated approval for manufacturing and marketing of …
Novartis fixes viewpoint as second-quarter deals, benefit fall Kumar Jeetendra | July 21, 2020 Swiss drugmaker Novartis reduced its 2020 sales outlook on Tuesday after second quarter earnings and profit fell, as hospitals which stocked up on medicines during the first-quarter on account of this COVID-19 pandemic slowed buys. Net income in the three months through June dropped 4% to $1.9 billion, compared to $2.1 billion in 2019. Earnings …
Drug discovery pipeline to exploit transcription factors for cancer therapy Kumar Jeetendra | July 21, 2020 Cancer is a major cause of death and among the most complicated challenges to contemporary medication. By employing cutting-edge technologies that precisely measure the effects of candidate targets and drugs on the fundamental process of transcription, the new start-up firm QUANTRO Therapeutics tries to radically change the precision and range of cell-based drug screening. QUANTRO’s …
